Skip to main content

Table 1 Summary of the immunorectivity to MT 1/2 in human BPH and prostate adenocarcinoma tissues

From: Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues

Case no.

Grade*

MT1/2 IHC scorea**

  

BPHb

Prostatic carcinoma

1

3

++

Negative

2

3

++

Negative

3

1

++

Negative

4

2

++

+

5

3

++

Negative

6

N/A

+++

N/A

7

2

++

Negative

8

N/A

++

N/A

9

1

++

Negative

10

3

++

Negative

11

2

++

Negative

12

3

++

Negative

13

2

++

Negative

14

2

++

Negative

15

3

+

Negative

16

N/A

++

N/A

17

N/A

++

N/A

18

2

++

++

19

2

++

+

20

N/A

+

N/A

21

3

++

Negative

22

2

++

++

23

3

+

++

  1. Slides were prepared from formalin fixed paraffin embedded tissues.
  2. * Gleason grade evaluated using WHO standard [41]
  3. a** Semi-quantitative scoring of immunoreactivity was done as follows [40]:
  4. Negative, no positive cells; score +, <10% positive cells; score ++, 10–50% positive cells; score +++, > 50% positive cells
Back to article page

Molecular Cancer

ISSN: 1476-4598